By Kosaku Narioka Takeda Pharmaceutical is scheduled to report its third-quarter results on Thursday. Here is what you need to know: NET PROFIT FORECAST:.
By Ben Glickman Takeda's treatment for a rare blood clotting disorder received approval from the U.S. Food and Drug Administration. The FDA said Thursday it.
By Paul Ziobro Shares of Neurocrine Biosciences fell in late trading after the biopharmaceutical company said that two studies failed to achieve desired.
By Kosaku Narioka Takeda Pharmaceutical shares fell sharply after it reported a second-quarter net loss due to impairments on certain products and cut its.
By Kosaku Narioka Takeda Pharmaceutical is scheduled to report second-quarter results on Thursday. Here is what you need to know: NET PROFIT FORECAST: Takeda.